Collectively, our results suggested that HR488B might be a promising candidate for CRC treatment and that targeting the E2F1/Rb/HDAC1 complex provides a rationale for future evaluation of HR488B as a potential drug in CRC. The gene discussed is HDAC1; the disease is colorectal carcinoma.